Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer.
Amelia Bruce Zelnak
No relevant relationships to disclose
Elisavet Paplomata
No relevant relationships to disclose
Sujatha Murali
No relevant relationships to disclose
Geetha D. Vallabhaneni
No relevant relationships to disclose
Virginia G. Kaklamani
Honoraria - Genentech; Novartis
Xiaoxian Li
No relevant relationships to disclose
Yuan Liu
No relevant relationships to disclose
Ruth O'Regan
Consultant or Advisory Role - Novartis
Research Funding - Genentech